如瑞迪博士 RDY 深滬

等待開盤 03-26 09:30:00 美东时间

13.87

+0.420

+3.12%

華盛通

立即下載

最高13.97
今開13.85
成交量 176.71万股
最低 13.785
昨收 13.45
總市值 115.48亿
52周最高 16.0985
市盈率 ^靜 17.30
換手率 0.21%
52周最低 12.1885
委比 4.37%
總股本 8.33亿
歷史最高 16.8205
量比 0.56
振幅 1.38%
歷史最低 4.667
每手 1
風險率 0.61%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply

India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks.

03-23 21:00
'Dr Reddy's aims to launch generic obesity drug at 60% discount' - Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/dr-reddys-aims-launch-generic-obesity-drug-60-discount-2026-02-17/

02-17 23:07
美股盘后 | PTC Inc.涨2.47%，美洲移动涨2.32%

PTC Inc.涨2.47%；美洲移动涨2.32%；亚玛芬体育涨2.31%

01-24 07:10
期权扫描 | Meta期权成交激增！一末日CALL单暴力上涨逾4000%；奈飞获大单押注反弹至100美元

Meta期权成交激增1.2倍！一末日CALL单暴力上涨逾4000%；奈飞获大单押注反弹至100美元，收购华纳案迎美国参议院听证会>>

01-23 19:58
Dr Reddy's Laboratories Q3 EPS $0.16, Inline, Sales $978.820M Beat $978.100M Estimate

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 18.5 percent decrease over earnings of $0.20 per share from the same period last year.

01-22 07:03
'Dr Reddy's to Start Selling Generic Ozempic in India From March' - Bloomberg

https://www.bloomberg.com/news/articles/2026-01-21/dr-reddy-s-to-start-selling-generic-ozempic-in-india-from-march?srnd=homepage-europe&embedded-checkout=true

01-21 23:06
Dr. Reddy's Laboratories Rolls Out Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution UPS 0.7%

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride

01-14 21:50
美股盘前 | Revolution Medicines涨16.23%，Rocket Companies, Inc. Class A涨7.49%

Revolution Medicines涨16.23%；Rocket Companies, Inc. Class A涨7.49%；如瑞迪博士涨4.64%

01-09 17:23
Dr. Reddy's Switzerland Receives FDA Complete Response Letter For AVT03 Denosumab Biosimilar BLA Following Manufacturing Inspection Findings

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015This is to inform you that Dr. Reddy's Laboratories SA, Switzerland, wholly owned subsidiary of theCompany

2025-12-31 22:31
美股盘后 | 诺和诺德涨10.81%，亨廷顿英格尔斯工业涨4.46%

诺和诺德涨10.81%；亨廷顿英格尔斯工业涨4.46%；Aptiv Plc涨3.46%

2025-12-23 07:11

派息除權日	每股總股息	派息日期
2025-07-25	0.07
2024-07-30	0.41	2024-07-30
2023-07-28	0.41	2023-07-28
2022-08-01	0.32	2022-08-01
2022-07-08	0.32	2022-07-08
2021-07-30	0.28	2021-07-30
2021-07-08	0.28	2021-07-08
2020-07-10	0.27	2020-07-10
2019-07-12	0.27	2019-07-12
2018-07-13	0.27	2018-08-09
2017-07-13	0.29	2017-08-10
2016-07-14	0.28	2016-08-09
2015-07-08	0.29	2015-08-17
2014-08-01	0.27	2014-08-15
2013-07-10	0.23	2013-08-15
2012-06-27	0.23	2012-08-06
2011-06-29	0.23	2011-08-11
2011-06-14	0.64	2011-06-23
2010-06-30	0.22	2010-08-17
2009-07-02	0.11	2009-08-12
2008-07-03	0.07	2008-08-18
2007-07-06	0.07	2007-08-10
2006-07-07	0.11	2006-08-21
2005-07-07	0.11	2005-08-16
2004-07-15	0.11	2004-08-24
2003-08-07	0.11	2003-10-02
2002-08-08	0.05	2002-09-30
2001-11-20	0.10	2001-12-13

公司名稱	如瑞迪博士
行業分類	制药
業務描述	Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

如瑞迪博士 RDY 深 滬

13.87

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

如瑞迪博士 RDY 深滬